Clinical Trial Update: Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ-64565111 in Type 2 diabetes mellitus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• JNJ-64565111

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: TERMINATED